Clinical Trials
5
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:4
Phase 2:1
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
4 (80.0%)Phase 2
1 (20.0%)A Phase I Pharmacokinetics Study for KT07 Capsule
Phase 1
Completed
- Conditions
- Healthy Adult SubjectsPharmacokineticsSafety and Tolerability
- Interventions
- Drug: Low dose KT07Drug: High dose KT07Drug: Low dose PlaceboDrug: High dose Placebo
- First Posted Date
- 2022-02-04
- Last Posted Date
- 2022-10-17
- Lead Sponsor
- Yiling Pharmaceutical Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT05223660
- Locations
- 🇺🇸
Pharmaron, Baltimore, Maryland, United States
A Clinical Study Trial of Phenlarmide in China
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: Phenlarmide TabletsDrug: Placebos
- First Posted Date
- 2019-11-15
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Yiling Pharmaceutical Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT04164121
- Locations
- 🇨🇳
Peking union medical college hospital, Beijing, Beijing, China
A Single-dose Study to Investigate the Tolerance and Pharmacokinetics of Finamine Tablets in China
Phase 1
Completed
- Conditions
- Parkinson Disease
- Interventions
- Drug: Finamine tabletsDrug: Placebo tablets
- First Posted Date
- 2019-11-14
- Last Posted Date
- 2021-12-14
- Lead Sponsor
- Yiling Pharmaceutical Inc.
- Target Recruit Count
- 34
- Registration Number
- NCT04162275
- Locations
- 🇨🇳
Shijiazhuang Yiling Pharmaceutical Co. Ltd, Shijiazhuang, Hebei, China
A Phase I Clinical Study Trial of Felbinac Trometamol Injection in China
- First Posted Date
- 2017-08-01
- Last Posted Date
- 2019-11-18
- Lead Sponsor
- Yiling Pharmaceutical Inc.
- Target Recruit Count
- 58
- Registration Number
- NCT03235778
- Locations
- 🇨🇳
The First Hospital of Jilin University, Chang Chun, Jilin, China
A Clinical Trial of KT07 Capsule in the U.S.A
Phase 2
Completed
- Conditions
- Influenza, Human
- Interventions
- Drug: KT07 CapsuleOther: Placebo
- First Posted Date
- 2016-08-15
- Last Posted Date
- 2020-08-31
- Lead Sponsor
- Yiling Pharmaceutical Inc.
- Target Recruit Count
- 391
- Registration Number
- NCT02867358
- Locations
- 🇺🇸
Central Alabama Research, Birmingham, Alabama, United States
🇺🇸Parkway Medical Center, LLC, Birmingham, Alabama, United States
🇺🇸Cahaba Research, Inc., Birmingham, Alabama, United States
News
No news found